NCT02254265View on ClinicalTrials.gov

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

455

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Keratoconjunctivitis SiccaDry Eye Disease

Interventions

DRUG

OTX-101 0.05%

OTX-101 0.05% Ophthalmic Solution

DRUG

OTX-101 0.09%

OTX-101 0.09% Ophthalmic Solution

DRUG

Vehicle

Vehicle of OTX-101 Ophthalmic Solution

Trial Locations (1)

Unknown

Cleveland

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca | Biotech Hunter | Biotech Hunter